Phase 2Completed

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy (ROSE)

A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to High-Intensity Statin Therapy

Sponsor
NewAmsterdam Pharma (Industry)
Enrollment
120 enrolled
Conditions
Dyslipidemias; High Cholesterol; Hypercholesterolemia
Interventions
Obicetrapib
Ages
adults, older adults
Registry
NCT04753606

Full record on ClinicalTrials.gov

From the registry

This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.

Primary outcomes

  • Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
  • Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
  • LS Mean Percent Change Iin Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
  • Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered